Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen reported third-quarter 2026 revenue of $209 million, up 11% year over year as reported and 12.5% organically. The company completed its acquisition of BioLife Solutions to strengthen its position in the cell therapy market. Repligen raised its full-year revenue guidance to $844 million–$852 million, representing projected growth of 14.5%–15.5%, citing the acquisition, improving end-market demand, healthy consumables and services trends, and a growing capital equipment order book.